Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMS | P04818 | 1/20 | 0.70 |
| ▸ | PDE2A | O00408 | 14/20 | 0.65 |
| ▸ | PDE10A | Q9Y233 | 11/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 2/20 | 0.58 |
| ▸ | MEN1 | O00255 | 1/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14765203 | 0.86 | MAOA (0.67) | TYMSPDE2APDE10AMAOAKDM4E | |
| SCHEMBL17356919 | 0.85 | PDE2A (0.62) | TYMSPDE2APDE10A | |
| SCHEMBL10847181 | 0.83 | TYMS (1.00) | TYMSPDE2APDE10AMAOAKDM4E | |
| SCHEMBL14359766 | 0.82 | PDE2A (0.58) | TYMSPDE2APDE10AKDM4EALDH1A1 | |
| SCHEMBL14359717 | 0.80 | PDE2A (0.62) | PDE2APDE10AMAOA | |
| SCHEMBL14359691 | 0.80 | PDE2A (0.76) | PDE2APDE10AMAOA | |
| SCHEMBL14362116 | 0.80 | PDE2A (0.76) | TYMSPDE2APDE10A | |
| SCHEMBL12502454 | 0.79 | PDE2A (0.71) | PDE2APDE10A | |
| SCHEMBL12502893 | 0.79 | PDE2A (1.00) | PDE2APDE10AMAOA | |
| SCHEMBL12502142 | 0.79 | PDE2A (1.00) | PDE2APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | claimed |
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | JANSSEN PHARMACEUTICA NV (BE) | 2014-05-29 | — | — | US | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
| WO-2013034755-A1 | TRIAZOLOPYRAZINE DERIVATIVES AND THEIR USE FOR TREATING NEUROLOGICAL AND PSYCHIATRIC DISORDERS | H. LUNDBECK A/S (DK) | 2013-03-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140147386-A1 | 1-ARYL-4-METHYL-[1,2,4]TRIAZOLO[4,3-a]QUINOXALINE DERIVATIVES | PDE2A, PDE12, PDE5A | TYMS 1183/4885PDE2A 1/4885PDE10A 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.